 <h1>Orbactiv Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>oritavancin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about oritavancin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Orbactiv.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to oritavancin: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, oritavancin (the active ingredient contained in Orbactiv) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking oritavancin:</p><p>
<i>Less common</i>
</p><ul>
<li>Changes in skin color</li>
<li>dry, red, hot, or irritated skin</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>pain, swelling, or tenderness in the skin</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>fever</li>
<li>hives, itching skin, or rash</li>
<li>increase in bone pain</li>
<li>joint pain, stiffness, or swelling</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>redness, soreness, or itching skin</li>
<li>sores, welting, or blisters</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach tenderness</li>
<li>severe abdominal or stomach cramps and pain</li>
<li>watery and severe diarrhea, which may also be bloody</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of oritavancin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common or rare</i>
</p><ul>
<li>Dizziness</li>
<li>headache</li>
<li>nausea or vomiting</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to oritavancin: intravenous powder for injection</i></p><h3>General</h3><p>In pooled clinical trials, serious side effects were reported in 5.8% of patients treated with this drug (compared to 5.9% treated with vancomycin).  Cellulitis was the serious side effect reported most often with both drugs.</p>
<p></p>
<p>This drug was discontinued due to side effects in 3.7% of patients, most often due to cellulitis and osteomyelitis.</p>
<p></p>
<p>The most commonly reported side effects included nausea, headache, vomiting, limb and subcutaneous abscesses, and diarrhea.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Cellulitis, limb abscess, pruritus, rash, subcutaneous abscess, urticaria</p>
<p><b>Uncommon</b> (0.1% to 1%): Erythema multiforme, leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, diarrhea, nausea, vomiting</p>
<p><b>Frequency not reported</b>: Clostridium difficile associated diarrhea<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function tests, increased ALT, increased AST</p>
<p><b>Uncommon</b> (0.1% to 1%): Blood bilirubin increased</p>
<p><b>Frequency not reported</b>: Increased total bilirubin<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site erythema, infusion site phlebitis, infusion site reactions<sup>[Ref]</sup></p><p>Infusion site reactions included extravasation, induration, infusion site erythema, infusion site phlebitis, peripheral edema, pruritus, and rash.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Extravasation, induration</p>
<p><b>Frequency not reported</b>: Infusion related reactions<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Peripheral edema, tachycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Flushing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Eosinophilia, thrombocytopenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Osteomyelitis, tenosynovitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Angioedema, hypersensitivity/hypersensitivity reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Bronchospasm, wheezing<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperuricemia, hypoglycemia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Orbactiv (oritavancin)." The Medicines Company, Parsippany, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Orbactiv (oritavancin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: glycopeptide antibiotics</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Orbactiv &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Skin and Structure Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to oritavancin: intravenous powder for injection</i></p><h3>General</h3><p>In pooled clinical trials, serious side effects were reported in 5.8% of patients treated with this drug (compared to 5.9% treated with vancomycin).  Cellulitis was the serious side effect reported most often with both drugs.</p><p></p><p>This drug was discontinued due to side effects in 3.7% of patients, most often due to cellulitis and osteomyelitis.</p><p></p><p>The most commonly reported side effects included nausea, headache, vomiting, limb and subcutaneous abscesses, and diarrhea.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Cellulitis, limb abscess, pruritus, rash, subcutaneous abscess, urticaria</p><p><b>Uncommon</b> (0.1% to 1%): Erythema multiforme, leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, diarrhea, nausea, vomiting</p><p><b>Frequency not reported</b>: Clostridium difficile associated diarrhea<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function tests, increased ALT, increased AST</p><p><b>Uncommon</b> (0.1% to 1%): Blood bilirubin increased</p><p><b>Frequency not reported</b>: Increased total bilirubin<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site erythema, infusion site phlebitis, infusion site reactions<sup>[Ref]</sup></p><p>Infusion site reactions included extravasation, induration, infusion site erythema, infusion site phlebitis, peripheral edema, pruritus, and rash.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Extravasation, induration</p><p><b>Frequency not reported</b>: Infusion related reactions<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Peripheral edema, tachycardia</p><p><b>Uncommon</b> (0.1% to 1%): Flushing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p><p><b>Uncommon</b> (0.1% to 1%): Eosinophilia, thrombocytopenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia</p><p><b>Uncommon</b> (0.1% to 1%): Osteomyelitis, tenosynovitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Angioedema, hypersensitivity/hypersensitivity reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Bronchospasm, wheezing<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperuricemia, hypoglycemia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Orbactiv (oritavancin)." The Medicines Company, Parsippany, NJ. </p><h2>More about Orbactiv (oritavancin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: glycopeptide antibiotics</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Orbactiv &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Skin and Structure Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>